{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T11:15:19Z","timestamp":1788261319598,"version":"build-2803163510"},"reference-count":90,"publisher":"Informa UK Limited","issue":"9","license":[{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["DK113423"],"award-info":[{"award-number":["DK113423"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["CA213201"],"award-info":[{"award-number":["CA213201"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["U54CA163072"],"award-info":[{"award-number":["U54CA163072"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["U54CA163066"],"award-info":[{"award-number":["U54CA163066"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Therapeutic Patents"],"published-print":{"date-parts":[[2026,9,2]]},"DOI":"10.1080\/13543776.2026.2708736","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T21:10:35Z","timestamp":1785186635000},"page":"781-795","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["A patent perspective of RSK inhibitors to treat cancer (2020-present)"],"prefix":"10.1080","volume":"36","author":[{"given":"Aviv","family":"Preminger","sequence":"first","affiliation":[{"name":"Vanderbilt University","place":["Nashville, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah A.","family":"Lannigan","sequence":"additional","affiliation":[{"name":"Vanderbilt University","place":["Nashville, USA"]},{"name":"Vanderbilt University Medical Center","place":["Nashville, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,7,29]]},"reference":[{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2025.08.001"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1080\/13543776.2016.1212839"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M408194200"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.00773-14"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2023.104699"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2024.105739"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1080\/14728222.2024.2433123"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.1027.65.3"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1021\/ml300298v"},{"key":"e_1_3_5_12_1","unstructured":"Hecht SM Maloney DJ inventors; UNIVERSITY OF VIRGINIA PATENT FOUNDATION assignee. SYNTHESIS OF INHIBITORS OF P90RSK patent WO2006086103. 2006."},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-3151"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1042\/BJ20061088"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1080\/14756366.2021.1957862"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15072023"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-55643-7"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jproteome.5c00690"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI185119"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2026.114662"},{"key":"e_1_3_5_21_1","unstructured":"Dunn S Jayanthan E Nagireddy A JR et al. inventors; PHOENIX MOLECULAR DESIGNS assignee. Carboxamide derivatives useful as rsk inhibitors. 2016."},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.e13043"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.4135"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-16-0106"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-17-2063"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/emboj\/20.13.3484"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-023-02755-5"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/cas.15280"},{"key":"e_1_3_5_29_1","article-title":"TAS0612, a novel RSK, AKT, and S6K inhibitor, exhibits antitumor effects in preclinical tumor models","author":"Ichikawa K","year":"2023","unstructured":"Ichikawa K, Ito S, Kato E, et al. TAS0612, a novel RSK, AKT, and S6K inhibitor, exhibits antitumor effects in preclinical tumor models. Mol Cancer Ther. 2023.","journal-title":"Mol Cancer Ther"},{"key":"e_1_3_5_30_1","unstructured":"Winnike R Mcpherson E Flahive E et al. inventors; PHOENIX MOLECULAR DESIGNS assignee. Crystalline forms of an RSK inhibitor. 2020."},{"key":"e_1_3_5_31_1","unstructured":"Chang S Chen X Yan N et al. inventors; KINOTECK THERAPEUTICS CO. LTD assignee. Carboxamide derivative having rsk inhibitory effect pharmaceutical composition comprising same and use thereof. 2023."},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.3390\/ph16081157"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.3390\/ph17030281"},{"key":"e_1_3_5_34_1","unstructured":"Li J Li X S GAO et al. inventors; Nanjing Sanhome Pharmaceutical Co Ltd assignee. Compounds as RSK2 inhibitors and uses thereof. 2022."},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1186\/bcr2889"},{"key":"e_1_3_5_36_1","unstructured":"Ma D Ren X Fang D et al. inventors; SHANGHAI KEENTAI BIOMEDICAL TECHNOLOGY assignee. Carboxamide derivative with RSK inhibition effect pharmaceutical composition containing carboxamide derivative and application of carboxamide derivative. 2023."},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2023.1297292"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2023.166996"},{"key":"e_1_3_5_39_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.1c00969"},{"issue":"1","key":"e_1_3_5_40_1","first-page":"368","article-title":"Design and structural optimization of orally bioavailable RSK4 inhibitors for the treatment of esophageal squamous cell carcinoma","volume":"69","author":"Leng L","year":"2026","unstructured":"Leng L, He S, Zhang M, et al. Design and structural optimization of orally bioavailable RSK4 inhibitors for the treatment of esophageal squamous cell carcinoma. J Med Chem. 2026;69(1):368\u2013386.","journal-title":"J Med Chem"},{"key":"e_1_3_5_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2021.153642"},{"key":"e_1_3_5_42_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aba4627"},{"key":"e_1_3_5_43_1","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.128078"},{"key":"e_1_3_5_44_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI134930"},{"key":"e_1_3_5_45_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI66343"},{"key":"e_1_3_5_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2023.08.060"},{"key":"e_1_3_5_47_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-015-0724-6"},{"key":"e_1_3_5_48_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232314569"},{"key":"e_1_3_5_49_1","doi-asserted-by":"publisher","DOI":"10.22074\/cellj.2016.4310"},{"key":"e_1_3_5_50_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12957-018-1474-7"},{"key":"e_1_3_5_51_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40360-022-00605-2"},{"key":"e_1_3_5_52_1","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S238132"},{"key":"e_1_3_5_53_1","doi-asserted-by":"publisher","DOI":"10.62347\/ZLEQ9498"},{"key":"e_1_3_5_54_1","doi-asserted-by":"publisher","DOI":"10.3892\/or.2019.7328"},{"key":"e_1_3_5_55_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11033-023-08609-9"},{"key":"e_1_3_5_56_1","unstructured":"Li H Li S Xu Y et al. inventors; UNIV EAST CHINA SCI & TECHNOLOGY assignee. Pteridone derivative as rsk inhibitor and application thereof. 2021."},{"key":"e_1_3_5_57_1","unstructured":"Ren P Wang X Gray NS et al. inventors; IRM LLC assignee. Compounds and compositions as protein kinase inhibitors. 2005."},{"key":"e_1_3_5_58_1","unstructured":"Li H Li S Qian X et al. inventors; UNIV EAST CHINA NORMAL UNIV EAST CHINA SCI & TECHNOLOGY UNIV ZHENGZHOU JINFENG LAB assignee. Pyrrolopyrimidine derivative as rsk inhibitor and use thereof. 2023."},{"key":"e_1_3_5_59_1","unstructured":"Li H Li S Qian X et al. inventors; UNIV EAST CHINA NORMAL UNIV EAST CHINA SCI & TECHNOLOGY UNIV ZHENGZHOU JINFENG LAB assignee. Pyridonopyrimidine derivative as rsk inhibitor and use thereof. 2023."},{"key":"e_1_3_5_60_1","unstructured":"Taunton J Cohen M Shokat K et al. inventors; UNIV CALIFORNIA assignee. Selective serine\/threonine kinase inhibitors. 2005."},{"key":"e_1_3_5_61_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.24675"},{"key":"e_1_3_5_62_1","unstructured":"Leng L Xu Y Zhao Z et al. inventors; UNIV ZHENGZHOU UNIV EAST CHINA SCI & TECHNOLOGY UNIV EAST CHINA NORMAL assignee. Pteridinone derivatives as RSK inhibitors and their applications. 2022."},{"key":"e_1_3_5_63_1","unstructured":"Jiang L Yuan Y Zhao Z et al. inventors; UNIV EAST CHINA SCI & TECHNOLOGY assignee. Pyrimidooxazine derivatives as RSK inhibitors and their applications. 2020."},{"key":"e_1_3_5_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2021.116220"},{"key":"e_1_3_5_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2019.115303"},{"key":"e_1_3_5_66_1","unstructured":"Casalvieri KA P R inventors; UNIV COLORADO assignee. Fused bicyclic pyrimidine derivatives and uses thereof. 2022."},{"key":"e_1_3_5_67_1","unstructured":"Wang Z Li M Chai J et al. inventors; UNIV FOURTH MILITARY MEDICAL CHINESE UNIV AIR FORCE MEDICAL assignee. Use of selonsertib in preparation of drug for treating cancer. 2023."},{"key":"e_1_3_5_68_1","doi-asserted-by":"publisher","DOI":"10.1159\/000369152"},{"key":"e_1_3_5_69_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.02.027"},{"key":"e_1_3_5_70_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.0000000000000444"},{"key":"e_1_3_5_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2018.10.007"},{"key":"e_1_3_5_72_1","unstructured":"Lapuerta P Levy DE S M inventors; 4M THERAPEUTICS INC assignee. N-desmethyl ruboxistaurin as a rsk inhibitor for therapeutic use. 2025."},{"key":"e_1_3_5_73_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm950588y"},{"key":"e_1_3_5_74_1","doi-asserted-by":"publisher","DOI":"10.1177\/03000605251396715"},{"key":"e_1_3_5_75_1","unstructured":"Peng Y Liu Y Wang K et al. inventors; UNIV CHINESE PEOPLES LIBERATION ARMY assignee. Application of APY29 in preparation of RSK4 kinase inhibitor. 2022."},{"key":"e_1_3_5_76_1","doi-asserted-by":"publisher","DOI":"10.1038\/nchembio.1094"},{"key":"e_1_3_5_77_1","unstructured":"Li M Chai J Q J inventors; XIAN INT MEDICAL CENT HOSPITAL assignee. Application of HG-14-10-04 in preparing medicament for treating esophageal squamous carcinoma. 2023."},{"key":"e_1_3_5_78_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.2c00168"},{"key":"e_1_3_5_79_1","doi-asserted-by":"publisher","DOI":"10.1111\/febs.14311"},{"key":"e_1_3_5_80_1","unstructured":"Han W Nam J Ki DH et al. inventors; CYRUS THERAPEUTICS INC BRIDGE BIOTHERAPEUTICS INC CYRUS THERAPEUTICS CO LTD assignee. Compound for targeted protein degradation and use thereof. 2023."},{"key":"e_1_3_5_81_1","unstructured":"Reigan P Matheson CJ C J inventors; UNIV COLORADO assignee. Amp-activated protein kinase inhibitors and methods of making and using the same. 2020."},{"key":"e_1_3_5_82_1","unstructured":"Reigan P C M inventors; UNIV COLORADO REIGAN P MATHESON C assignee. Conjugates of ampk inhibitors and protac degraders and related uses. 2021."},{"key":"e_1_3_5_83_1","unstructured":"Jiang D Deng Y Jiang S et al. inventors; UNIV CENT SOUTH assignee. A RSK2 inhibitor and its use. 2024."},{"key":"e_1_3_5_84_1","doi-asserted-by":"publisher","DOI":"10.2210\/pdb8xov\/pdb"},{"key":"e_1_3_5_85_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0008044"},{"key":"e_1_3_5_86_1","doi-asserted-by":"publisher","DOI":"10.1002\/pro.3235"},{"key":"e_1_3_5_87_1","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2011.61"},{"key":"e_1_3_5_88_1","doi-asserted-by":"publisher","DOI":"10.17179\/excli2025-8479"},{"key":"e_1_3_5_89_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2009.08.002"},{"key":"e_1_3_5_90_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M112.423046"},{"key":"e_1_3_5_91_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-016-2297-8"},{"key":"e_1_3_5_92_1","doi-asserted-by":"publisher","DOI":"10.1021\/bi300620c"}],"container-title":["Expert Opinion on Therapeutic Patents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543776.2026.2708736","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/13543776.2026.2708736","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543776.2026.2708736","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T10:26:11Z","timestamp":1788258371000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13543776.2026.2708736"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,29]]},"references-count":90,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9,2]]}},"alternative-id":["10.1080\/13543776.2026.2708736"],"URL":"https:\/\/doi.org\/10.1080\/13543776.2026.2708736","relation":{},"ISSN":["1354-3776","1744-7674"],"issn-type":[{"value":"1354-3776","type":"print"},{"value":"1744-7674","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,29]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ietp20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ietp20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-04-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}